Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ANI PHARMACEUTICALS | 10 | 5 | +8,73 % | ||
| AMNEAL PHARMACEUTICALS | 10 | - | 0,00 % | ||
| MODERNA | 9 | 16 | -0,41 % | ||
| PROTHENA | 7 | 1 | 0,00 % | ||
| CG ONCOLOGY | 7 | - | +4,78 % | ||
| NOVAVAX | 5 | 7 | -0,97 % | ||
| CARIS LIFE SCIENCES | 5 | - | +5,56 % | ||
| REGENERON PHARMACEUTICALS | 4 | 22 | 0,00 % | ||
| BEONE MEDICINES LTD ADR | 4 | 10 | +0,75 % | ||
| GILEAD SCIENCES | 4 | 5 | -0,33 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:59 | FDA Grants Accelerated Approval To Ascendis Pharma's YUVIWEL For Achondroplasia In Children | 8 | RTTNews | ||
| 05:59 | Aardvark Therapeutics Pauses Phase 3 Trial Of ARD-101 In Prader-Willi Syndrome; Stock Plunges | 7 | RTTNews | ||
| 05:29 | Prothena To Buy Back Up To $100 Mln Of Shares | 1 | RTTNews | ||
| 04:36 | Ascendis Pharma wins FDA approval for navepegritide for achondroplasia | 1 | Seeking Alpha | ||
| 04:30 | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | 324 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| 02:18 | Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange | 2 | Investing.com | ||
| 02:00 | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) | 109 | PR Newswire | Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study
PALYNZIQ is the... ► Artikel lesen | |
| 00:01 | Ascendis Pharma: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older | 41 | GlobeNewswire (Europe) | The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric... ► Artikel lesen | |
| Fr | Harrow Health Q4 2025 Earnings Preview | 3 | Seeking Alpha | ||
| Fr | Disc Medicine undergoes restructuring plan; slashes 20% of workforce | 4 | Seeking Alpha | ||
| Fr | Tectonic Therapeutic, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| Fr | Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval | 2 | Insider Monkey | ||
| Fr | Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure | 3 | Insider Monkey | ||
| Fr | P/E Ratio Insights for Gilead Sciences | 4 | Benzinga.com | ||
| Fr | What Analysts Are Saying About CG Oncology Stock | 1 | Benzinga.com | ||
| Fr | Adaptive Biotechnologies Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Fr | PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Prothena authorizes $100 million share buyback program | 1 | Investing.com | ||
| Fr | Novocure to Participate in 2026 Leerink Global Healthcare Conference | 197 | Business Wire | Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph... ► Artikel lesen | |
| Fr | Prothena kündigt Aktienrückkaufprogramm über 100 Mio. US-Dollar an | 2 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.